Breaking News, Collaborations & Alliances

Foundation Medicine, BMS Expand Companion Diagnostic Development Pact

Aims to develop FoundationOne CDx as a companion diagnostic for BMS’s investigational tyrosine kinase inhibitor, repotrectinib.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, entered into an expanded collaboration with Bristol-Myers Squibb to develop Foundation Medicine’s tissue-based test, FoundationOneCDx as a companion diagnostic for Bristol Myers Squibb’s investigational tyrosine kinase inhibitor, repotrectinib. Repotrectinib is an orally administered TKI (tyrosine kinase inhibitor) being evaluated in an ongoing registrational Phase 1/2 trial called TRIDENT-1 for patients with TKI-naive or...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters